Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Besmer, 1986, A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family, Nature, 320, 415, 10.1038/320415a0 Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 Berman, 2001, Gastrointestinal stromal tumor workshop, Human Pathol, 32, 578, 10.1053/hupa.2001.25484 DeMatteo, 2002, Clinical management of gastrointestinal stromal tumors, Human Pathol, 33, 466, 10.1053/hupa.2002.124122 Edmondson, 1999, Contrast of response to D-MAP+ sargramostatin between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas, Proc ASCO, 18, 541 Goss, 2000, Clinical and pathological characteristics of gastrointestinal stromal tumors, Proc ASCO, 19, 2203 Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, 1052, 10.1056/NEJM200104053441404 Blanke, 2001, Evaluation of the molecularly targeted therapy STI 571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT, Proc Am Soc Clin Oncol, 20, 2 Van Oosterom, 2001, Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumors, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7 Bilimoria, 2002, Tumor volume as a prognostic factor for sarcomatosis, Cancer, 94, 2441, 10.1002/cncr.10504